Clinical Trials · NCT00248157

Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy

Name: Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 3Octreotide

Phase: Phase 3
Recruitment status: Terminated
Sponsor: Novartis Pharmaceuticals
Enrollment: 105
Start date: Nov 2005
Locations: See registry
Primary endpoint: long-term safety and tolerability

View Octreotide compound reference